Art

J-GLOBAL ID：202002239063007533   Reference number：20A1015205

Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene

ABCG5またはABCG8遺伝子の変異を有する患者におけるエゼチミブ-アトルバスタチン併用療法の有益な効果【JST・京大機械翻訳】

Author (5)： Tada Hayato (Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan) ,  Okada Hirofumi (Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan) ,  Nomura Akihiro (Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan) ,  Takamura Masayuki (Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan) ,  Kawashiri Masa-aki (Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan)
Material： Lipids in Health and Disease (Web)
Volume： 19  Issue： 1  Page： 1-7  Publication year： 2020 
JST Material Number： U7391A  ISSN： 1476-511X  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Use of ezetimibe on top of sta...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A1015205&from=J-GLOBAL&jstjournalNo=U7391A") }}

Thesaurus term： *gene ,  mutation ,  miner(machine) ,  pathogenicity ,  *combination therapy ,  base line ,  effectiveness ,  gene frequency ,  hypercholesterolemia ,  electronic medical record ,  LDL cholesterol ,  medical record
Semi thesaurus term： *ABCG5 ,  *ABCG8 ,  遺伝子解析 , 【Automatic Indexing@JST】

Author keywords (5)： ABCG5 ,  ABCG8 ,  LDL cholesterol ,  Ezetimibe ,  Sitosterolemia

JST classification (2)： Clinical application of drugs acting on lipid metabolism  (GW13050X) ,  Treatment for metabolic diseases,nutritional diseases.  (GD05030F)

Substance index (1)： Ezetimibe

Reference (30)：

• Ann Intern Med; Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study; WB Kannel, WP Castelli, T Gordon; 90; 1979; 85-91; 10.7326/0003-4819-90-1-85; citation_id=CR1
• Lancet; Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials; C Baigent, L Blackwell, J Emberson, LE Holland, C Reith, N Bhala, R Peto, EH Barnes, A Keech, J Simes, R Collins; 376; 2010; 1670-1681; 10.1016/S0140-6736(10)61350-5; citation_id=CR2
• N Engl J Med; Mendelian randomization study of ACLY and cardiovascular disease; BA Ference, KK Ray, AL Catapano, TB Ference, S Burgess, DR Neff, C Oliver-Williams, AM Wood, AS Butterworth, E Angelantonio, J Danesh, JJP Kastelein, SJ Nicholls; 380; 2019; 1033-1042; 10.1056/NEJMoa1806747; citation_id=CR3
• Circ J; Do we expect any pleiotropic effect of Proprotein Convertase Subtilisin/Kexin type 9 inhibition for reducing cardiovascular events beyond low-density lipoprotein cholesterol reduction?; H Tada, MA Kawashiri, M Yamagishi; 81; 2017; 1098-1099; 10.1253/circj.CJ-17-0586; citation_id=CR4
• Circ J; Low-density lipoprotein cholesterol goal attainment rates by initial statin Monotherapy among patients with dyslipidemia and high cardiovascular risk in Japan - a retrospective database analysis; T Umeda, A Hayashi, A Harada, K Okuyama, CA Baxter, S Tokita, T Teramoto; 82; 2018; 1605-1613; 10.1253/circj.CJ-17-0971; citation_id=CR5

Terms in the title (8)： ABCG5 ,  ABCG8 ,  遺伝子 ,  変異 ,  患者 ,  エゼチミブ ,  アトルバスタチン ,  併用療法